Clinical Trial Applications - Stopped: Filter, Search, and view applications


Clear
Extended search...

Page 6 of 7, showing 10 Applications out of 68 total, starting on record 51, ending on 60

# Protocol No Study Title Investigator(s) & Site(s) Date Stopped

51.

ECCT/23/04/01   mRNA-1273-P203
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr Janet Oyieko
Site(s) in Kenya
1. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
2. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
3. KEMRI/USAMRD (Kericho county)
4. Victoria Biomedical Research Institute (Kisumu county)
5. Kenya Medical Research Institute/USAMRU (Kisumu county)
6. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
7. KEMRI/ CDC (Kisumu county)
8. KEMRI (Kisumu county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
Not recorded View

52.

ECCT/23/04/06   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr. Walter Otieno Otieno
Site(s) in Kenya
1. Kenya Medical Research Institute/USAMRU (Kisumu county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/USAMRD (Kericho county)
4. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
5. KEMRI CRDR - Clinical Research Nairobi (Siaya county)
6. KEMRI/ CDC (Kisumu county)
7. KEMRI (Kisumu county)
8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
Not recorded View

53.

ECCT/23/04/07   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr Benhards Ogutu
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. KEMRI/USAMRD (Kericho county)
3. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
4. KAVI Nairobi (Nairobi City county)
5. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
6. KEMRI/ CDC (Kisumu county)
7. KEMRI (Kisumu county)
8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
9. Kenya Medical Research Institute/USAMRU (Kisumu county)
 
Not recorded View

54.

ECCT/23/05/05   mRNA-1273-P203
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
2. KEMRI/USAMRD (Kericho county)
3. Victoria Biomedical Research Institute (Kisumu county)
4. Kenya Medical Research Institute/USAMRU (Kisumu county)
5. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
6. KEMRI/ CDC (Kisumu county)
7. KEMRI (Kisumu county)
8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
Not recorded View

55.

ECCT/23/09/03   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Simon Kariuki
Site(s) in Kenya
1. Kenya Medical Research Institute- Centre for Global Health Research (Kisumu county)
 
Not recorded View

56.

ECCT/23/09/04   GBT440-038Open-Label Extension
    An Open-Label Extension Study of Voxelotor Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials       
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children Hospital (Nairobi City county)
2. Kenya Medical Research Institute (KEMRI), Centre for Respiratory Diseases Research (CRDR) (Nairobi City county)
3. KEMRI CRDR SIAYA within Siaya County Referral Hospital Grounds (Siaya county)
4. Strathmore University Medical Center, Centre for Research in Therapeutic Sciences (Nairobi City county)
 
Not recorded View

57.

ECCT/23/10/04   ACCEDE OR Study
    Use of Continuous glucose monitoring devices among Type 1 diabetes patients followed up in CDiC clinics in Machakos, Nairobi and Kiambu counties in Kenya: A three-arm pragmatic study on effectiveness, feasibility, acceptability, and cost   
Principal Investigator(s)
1. Daniel Katambo Kiningu
Site(s) in Kenya
1. Machakos Level 5 Hospital (Machakos county)
2. Thika Level 5 Hospital (Kiambu county)
3. Kenya Diabetes Management and Information Centre (Machakos county)
 
Not recorded View

58.

ECCT/23/10/06   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Godfrey Allan Otieno
2. Dr Videlis Nduba
Site(s) in Kenya
1. KEMRI-Kondele Children’s Hospital (Kisumu county)
2. KEMRI CRDR Clinical Research Annex (Nairobi City county)
 
Not recorded View

59.

ECCT/23/12/03   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Benson Ochieng Singa
Site(s) in Kenya
1. Migori County Referral Hospital (Migori county)
 
Not recorded View

60.

ECCT/23/12/04   GBT021601 OLE
    An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants with Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial       
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Gertude\'s Children\'s Hospital (Nairobi City county)
2. CENTER FOR RESEARCH IN THERAPEUTIC SCIENCES-STRATHMORE UNIVERSITY MEDICAL CENTER (CREATES (Nairobi City county)
3. KENYA MEDICAL RESEARCH INSTITUTE- CENTER FOR RESPIRATORY DISEASE RESEARCH(CRDR) (Nairobi City county)
4. KEMRI CRDR SIAYA (Siaya county)
 
Not recorded View